Nanexa AB is a leading pharmaceutical company that specializes in developing long-acting injectable medicines. With their pioneering PharmaShell® technology, Nanexa aims to revolutionize the field of drug delivery by creating a new generation of innovative medications. Located in Uppsala, Sweden, Nanexa operates a world-class pilot facility and laboratories, where they develop their own product projects and collaborate with other pharmaceutical companies based on the PharmaShell® system.

Nanexa's strong commitment to research and development is evident in their recent accomplishments, including positive preclinical progress with NEX-22, favorable phase 1 data with NEX-20, and ongoing evaluation of several partner projects. They regularly publish financial reports and press releases to keep stakeholders informed. Uniquely positioned in the industry, Nanexa develops injectable medications with high drug load and atomic layer precision, ensuring superior effectiveness.

They also have collaborative agreements with renowned pharmaceutical companies such as AstraZeneca. For more information or to get in touch with Nanexa, visit their headquarters in Uppsala or contact them via phone or email